Skip to main content

Table 4 OS comparisons stratified by major clinicopathological factors

From: Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy with lobaplatin and docetaxel improves survival for patients with peritoneal carcinomatosis from abdominal and pelvic malignancies

Variables

Number

Median OS (mo)

95 % CI (mo)

P

Gender

0.955

 Male

41

22.7

6.2–39.2

 

 Female

59

24.2

14.2–34.2

 

Age (year)

0.608

 <60

71

22.7

13.4–32.0

 

 ≥60

29

25.9

7.0–44.8

 

Primary tumor

0.000

 Carcinoma of the stomach

30

15.7

10.8–20.6

 

 Carcinoma of the colorectum

41

14.9

7.9–21.9

 

 Pseudomyxoma peritonei

13

Not reached

Not reached

 

 Carcinoma of ovary and primary peritoneum

16

34.6

22.1–47.1

 

Neoadjuvant chemotherapy

0.128

 No

53

31.2

18.4–44.0

 

 Yes

47

20.7

11.6–29.8

 

PC timing

0.086

 Synchronous

80

27.5

18.1–36.9

 

 Metachronous

20

13.2

10.6–15.8

 

PCI scores

0.000

 ≤20

44

46.1

10.7–81.5

 

 >20

56

16.3

8.6–24.0

 

CC scores

0.000

 0–1

63

42.9

28.3–57.5

 

 2–3

37

13.6

10.6–15.6

 

Postoperative chemotherapy cycles

0.000

 <6

49

14.1

9.6–18.6

 

 ≥6

51

31.9

24.1–39.7

 

SAE

0.007

 No

86

31.2

20.5–41.9

 

 Yes

14

12.2

9.5–15.0

 

Ascites

   

0.095

 ≤1000 mL

63

24.2

13.5–34.9

 

 >1000 mL

37

21.2

4.8–37.7

 
  1. In the original surgery calculation
  2. OS overall survival, mo months